Anti-inflammatory agent 31

Cat. No.:	HY-150587	
Molecular Formula:	C ₁₉ H ₃₀ O ₃	
Molecular Weight:	306.44	
Target:	ERK; NF-ĸB	
Pathway:	MAPK/ERK Pathway; Stem Cell/Wnt; NF-κB	
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.	



Inhibitors • Screening Libraries • Proteins

Description Anti-inflammatory agent 31 (enone 17) is a kind of andrographolide derivatives, is a anti-inflammatory agent. Anti- inflammatory agent 31 shows recovery effective of the intracellular GSH levels and protective effect on liver ¹¹ . IC ₅₀ & Target ERK1 ERK2 In Vitro Anti-inflammatory agent 31 (enone 17) (100, 200, and 400 µM; 24 h) prevents the DNA binding of the activated NF-kB p50 subunit in a dose-dependent manner ¹¹ . Anti-inflammatory agent 31 reacts as a quick rate (KGsH=0.076 M ⁻¹ , H ⁻¹) and long half-live (T _{1/2} =6.47 h) ^[11] . Anti-inflammatory agent 31 (s.20, and 50 µM; 24 h) shows recovery effective of the intracellular GSH levels, and (5 µM) induced more than 2.5 fold increase in GSH levels as compared to the basal levels ¹¹ . Anti-inflammatory agent 31 (s.20, and 50 µM; 24 h) displays low cytotoxicity in LO2 and HEK293 cells with CC ₅₀ of 14.68, 26.25 µM, respectively ¹¹ . Met has not independently confirmed the accuracy of these methods. They are for reference only. Immunofluorescence ^{[11} In Vivo Anti-inflammatory agent 31 (
Description Anti-inflammatory agent 31 (=none 17) is a kind of andrographolide derivatives, is a anti-inflammatory agent Anti-inflammatory agent 31 inhibits NF-xB activation by upstream blockade of PI3K/Akt and ERK1/2 MAPK activation. Anti-inflammatory agent 31 ishows recovery effective of the intracellular GSH levels and protective effect on liver ¹³ . Ir Cose & Target ERK1 ERK2 In Vitro Anti-inflammatory agent 31 (=none 17) (100, 200, and 400 μM; 24 h) prevents the DNA binding of the activated NF-xB p50 subunit in a dose-dependent maner ¹³ . Anti-inflammatory agent 31 (=none 17) (100, 200, and 400 μM; 24 h) and long half-live (T ₁₂ =647 h) ¹³¹ . Anti-inflammatory agent 31 (=none 17) (100, 200, and 50 μM; 24 h) shows recovery effective of the intracellular GSH levels, and (5 μM) induced more than 2.5-fold increase in GSH levels as compared to the basal levels ¹³¹ . Anti-inflammatory agent 31 (=none 17) (100, 200, and 50 μM; 24 h) shows recovery effective of the intracellular GSH levels, and (5 μM) induced more than 2.5-fold increase in GSH levels as compared to the basal levels ¹³¹ . Anti-inflammatory agent 31 (=so (and 50 μM; 24 h) shows recovery effective of the intracellular GSH levels, and (5 μM) induced more than 2.5-fold increase in GSH levels as compared to the basal levels ¹³¹ . Anti-inflammatory agent 31 (=so (and 50 μM; 24 h) shows recovery effective of the intracellular GSH levels, and (5 μM) induced more than 2.5-fold increase in GSH levels as Compared to the basal levels ¹³¹ . Anti-inflammatory agent 31 (=so (and EW) biolog cells Concentration: 5, 10, 20 μM In Vivo Anti-inflammatory agent 31 (=so (a	BIOLOGICAL ACTIVITY			
IC ₅₀ & Target ERK1 ERK2 In Vitro Anti-inflammatory agent 31 (=>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>	Description	Anti-inflammatory agent 31 (enone 17) is a kind of andrographolide derivatives, is a anti-inflammatory agent. Anti- inflammatory agent 31 inhibits NF-κB activation by upstream blockade of PI3K/Akt and ERK1/2 MAPK activation. Anti- inflammatory agent 31 shows recovery effective of the intracellular GSH levels and protective effect on liver ^[1] .		
In Vitro Anti-inflammatory agent 31 (enone 17) (100, 200, and 400 μM; 24 h) prevents the DNA binding of the activated NF-κB p50 subunit in a dose-dependent manner ^[1] . Anti-inflammatory agent 31 reacts as a quick rate (K _{GSH} =0.076 M ⁻¹ , h ⁻¹) and long half-live (T _{1/2} =6.47 h) ^[1] . Anti-inflammatory agent 31 (s, 20, and 50 μM; 24 h) shows recovery effective of the intracellular GSH levels, and (5 μM) induced more than 2.5-fold increase in GSH levels as compared to the basal levels ^[1] . Anti-inflammatory agent 31 (s, 20, and 50 μM; 24 h) displays low cytotoxicity in LO2 and HEK293 cells with CC ₅₀ of 14.68, 26.25 μM, respectively ^[1] . Anti-inflammatory agent 31 (s, 20, and 50 μM; 24 h) displays low cytotoxicity in LO2 and HEK293 cells with CC ₅₀ of 14.68, 26.25 μM, respectively ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Immunofluorescence ^[1] Cell Line: RAW-blue TM cells Concentration: 5, 10, 20 μM Incubation Time: 24 hours Result: Inhibited the LPS-induced NF-κB activity and indicated the anti-inflammatory properties. In Vivo Anti-inflammatory agent 31 (-none 17) (i.p.; 0.3, 1.0 mg/kg) decreases total white blood cell and neutrophils counts, and alleviates LPS-induced acute lung injury in a dose-dependent manner in mouse ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Anti-inflammatory agent 31 (-nong/kg Anti-inflammatory	IC ₅₀ & Target	ERK1	ERK2	
Cell Line:RAW-blue TM cellsConcentration:5,10,20 μMIncubation Time:24 hoursResult:Inhibited the LPS-induced NF-κB activity and indicated the anti-inflammatory properties.In VivoAnti-inflammatory agent 31 (one 17) (i.p.; 0.3, 1.0 mg/kg) decreases total white blood cell and neutrophils counts, and alleviates LPS-induced acute lung injury in a dose-dependent manner in mouse ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.Animal Model:LPS-induced acute lung injury (ALI) mouse model (female BALB/c mice; 7-week-old) ^[1] Dosage:0.3, 1.0 mg/kgAdministration:Intraperitoneal injection 1 h after LPS challenge; twice daily for 4 days	In Vitro	Anti-inflammatory agent 31 (enone 17) (100, 200, and 400 μ M; 24 h) prevents the DNA binding of the activated NI subunit in a dose-dependent manner ^[1] . Anti-inflammatory agent 31 reacts as a quick rate (K _{GSH} =0.076 M ⁻¹ .h ⁻¹) and long half-live (T _{1/2} =6.47 h) ^[1] . Anti-inflammatory agent 31 (5, 20, and 50 μ M; 24 h) shows recovery effective of the intracellular GSH levels, and induced more than 2.5-fold increase in GSH levels as compared to the basal levels ^[1] . Anti-inflammatory agent 31 (5, 20, and 50 μ M; 24 h) displays low cytotoxicity in LO2 and HEK293 cells with CC ₅₀ of 26.25 μ M, respectively ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Immunofluorescence ^[1]		
Concentration:5, 10, 20 μMIncubation Time:24 hoursResult:Inhibited the LPS-induced NF-κB activity and indicated the anti-inflammatory properties.In VivoAnti-inflammatory agent 31 cone 17) (i.p.; 0.3, 1.0 mg/kg) decreases total white blood cell and neutrophils counts, and alleviates LPS-induced acute lung injury in a dose-dependent manner in mouse ^[1] . MCE has not independentty-orfirmed the accuracy of these methods. They are for reference only.Animal Model:LPS-induced acute lung injury (ALI) mouse model (female BALB/c mice; 7-week-old) ^[1] Dosage:0.3, 1.0 mg/kgAdministration:Intraperitoneal injection 1 h after LPS challenge; twice daily for 4 days		Cell Line:	RAW-blue TM cells	
Incubation Time:24 hoursResult:Inhibited the LPS-induced NF-kB activity and indicated the anti-inflammatory properties.In VivoAnti-inflammatory agent 31 (one 17) (i.p.; 0.3, 1.0 mg/kg) decreases total white blood cell and neutrophils counts, and alleviates LPS-induced acute 107 (injury in a dose-dependent manner in mouse ^[1] . MCE has not independent! MCE has not independent!Animal Model:LPS-induced acute lung injury (ALI) mouse model (female BALB/c mice; 7-week-old) ^[1] Dosage:Dosage:0.3, 1.0 mg/kgAdministration:Intraperitoneal injection 1 h after LPS challenge; twice daily for 4 days		Concentration:	5, 10, 20 μΜ	
Result:Inhibited the LPS-induced NF-κB activity and indicated the anti-inflammatory properties.In VivoAnti-inflammatory agent 31 (=none 17) (i.p.; 0.3, 1.0 mg/kg) decreases total white blood cell and neutrophils counts, and alleviates LPS-induced acute lung injury in a dose-dependent manner in mouse ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.Animal Model:LPS-induced acute lung injury (ALI) mouse model (female BALB/c mice; 7-week-old) ^[1] Dosage:0.3, 1.0 mg/kgAdministration:Intraperitoneal injection 1 h after LPS challenge; twice daily for 4 days		Incubation Time:	24 hours	
In VivoAnti-inflammatory agent 31 (enone 17) (i.p.; 0.3, 1.0 mg/kg) decreases total white blood cell and neutrophils counts, and alleviates LPS-induced acute lung injury in a dose-dependent manner in mouse ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.Animal Model:LPS-induced acute lung injury (ALI) mouse model (female BALB/c mice; 7-week-old) ^[1] Dosage:0.3, 1.0 mg/kgAdministration:Intraperitoneal injection 1 h after LPS challenge; twice daily for 4 days		Result:	Inhibited the LPS-induced NF-κB activity and indicated the anti-inflammatory properties.	
Animal Model:LPS-induced acute lung injury (ALI) mouse model (female BALB/c mice; 7-week-old)Dosage:0.3, 1.0 mg/kgAdministration:Intraperitoneal injection 1 h after LPS challenge; twice daily for 4 days	In Vivo	Anti-inflammatory agent 31 (enone 17) (i.p.; 0.3, 1.0 mg/kg) decreases total white blood cell and neutrophils counts, and alleviates LPS-induced acute lung injury in a dose-dependent manner in mouse ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.		
Dosage:0.3, 1.0 mg/kgAdministration:Intraperitoneal injection 1 h after LPS challenge; twice daily for 4 days		Animal Model:	LPS-induced acute lung injury (ALI) mouse model (female BALB/c mice; 7-week-old) $^{\left[1 ight]}$	
Administration: Intraperitoneal injection 1 h after LPS challenge; twice daily for 4 days		Dosage:	0.3, 1.0 mg/kg	
		Administration:	Intraperitoneal injection 1 h after LPS challenge; twice daily for 4 days	

Result:

REFERENCES

[1]. Tran QTN, Tan DWS, Wong WSF, Chai CLL. From irreversible to reversible covalent inhibitors: Harnessing the andrographolide scaffold for anti-inflammatory action. Eur J Med Chem. 2020 Oct 15;204:112481.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA